Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
Perioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives to monitor relapse risk. Intratumoral B-cells are increasingly...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2513109 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850132837318000640 |
|---|---|
| author | Belén Sierra Rodero Cristina Martínez-Toledo Ernest Nadal Marta Molina-Alejandre Rosario García Campelo Ángeles Gil-González Bartomeu Massuti Aránzazu García-Grande Manuel Dómine Amelia Insa Javier de Castro Carpeño Gerardo Huidobro Vence Margarita Majem Alex Martinez-Marti Diego Megias Daniel Lobato Ana Collazo-Lorduy Virginia Calvo Mariano Provencio Alberto Cruz-Bermúdez |
| author_facet | Belén Sierra Rodero Cristina Martínez-Toledo Ernest Nadal Marta Molina-Alejandre Rosario García Campelo Ángeles Gil-González Bartomeu Massuti Aránzazu García-Grande Manuel Dómine Amelia Insa Javier de Castro Carpeño Gerardo Huidobro Vence Margarita Majem Alex Martinez-Marti Diego Megias Daniel Lobato Ana Collazo-Lorduy Virginia Calvo Mariano Provencio Alberto Cruz-Bermúdez |
| author_sort | Belén Sierra Rodero |
| collection | DOAJ |
| description | Perioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives to monitor relapse risk. Intratumoral B-cells are increasingly recognized for their role in enhancing immunotherapy outcomes, yet the contribution of peripheral B-cells to immune surveillance remains unexplored. Peripheral B-cell immunophenotypes were analyzed from blood samples (at diagnosis, post-neoadjuvant, and at 6- and 12-months of adjuvant treatment) in 41 stage IIIA NSCLC patients treated with perioperative nivolumab plus chemotherapy, included in the NADIM clinical trial (NCT03081689). Results were correlated with 5-year survival outcomes and validated through unsupervised clustering. An increase in the percentage of total B-cells (CD19+CD20+) and naïve B-cells (CD19+CD20+CD24+CD38+CD27−CD10−), along with a reduction in CD20 expression on total B-cells, a decrease in the proportion of memory B-cells (CD19+CD20+CD24+CD38−/lowCD27+) and transitional B-cells (CD19+CD20+CD24++CD38++CD10+), was observed during the time encompassed between the end of neoadjuvant treatment and the posterior 6 months of adjuvant treatment. Higher levels of CD20 expression on total B-cells, along with an increased percentage of memory B-cells, or activated B-cells (CD19+CD20+CD25+), at 6- and 12-months of adjuvant treatment, were associated with increased survival. Conversely, higher levels of a newly described circulating population of CD19+CD20lowCD25lowCD27low B-cells during adjuvant treatment were linked to disease progression. Perioperative nivolumab plus chemotherapy in resectable NSCLC patients induces significant changes in peripheral B-cells. The persistence of circulating memory B-cells during adjuvant treatment might play a crucial role in survival. |
| format | Article |
| id | doaj-art-7db2ffc596d54ec7b5c705b0cd67d28a |
| institution | OA Journals |
| issn | 2162-402X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-7db2ffc596d54ec7b5c705b0cd67d28a2025-08-20T02:32:07ZengTaylor & Francis GroupOncoImmunology2162-402X2025-12-0114110.1080/2162402X.2025.2513109Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)Belén Sierra Rodero0Cristina Martínez-Toledo1Ernest Nadal2Marta Molina-Alejandre3Rosario García Campelo4Ángeles Gil-González5Bartomeu Massuti6Aránzazu García-Grande7Manuel Dómine8Amelia Insa9Javier de Castro Carpeño10Gerardo Huidobro Vence11Margarita Majem12Alex Martinez-Marti13Diego Megias14Daniel Lobato15Ana Collazo-Lorduy16Virginia Calvo17Mariano Provencio18Alberto Cruz-Bermúdez19Servicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainInstitut Català d’Oncologia (ICO), Oncobell Program, IDIBELL. L’Hospitalet De Llobregat, Barcelona, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainServicio de Oncología Médica, Hospital Universitario A Coruña, A Coruña, A Coruña, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainServicio de Oncología Médica, Hospital General Dr. Balmis de Alicante, ISABIAL, Alicante, SpainFlow Cytometry Core Facility, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Madrid, SpainServicio de Oncologia Médica, Hospital Universitario Fundación Jiménez Díaz, Madrid, SpainFundación INCLIVA, Servicio de Oncología Médica, Hospital Clínico Universitario de Valencia, Valencia, SpainServicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain, Servicio de Oncología Médica, Hospital Alvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo, SpainServicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainVall Hebron Institute of Oncology (VHIO), Servicio de Oncología Médica, Hospital Universitari Vall d’Hebrón, Barcelona, SpainUnidad de Microscopía Óptica Avanzada, Instituto de Salud Carlos III, Majadahonda, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainServicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, SpainPerioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives to monitor relapse risk. Intratumoral B-cells are increasingly recognized for their role in enhancing immunotherapy outcomes, yet the contribution of peripheral B-cells to immune surveillance remains unexplored. Peripheral B-cell immunophenotypes were analyzed from blood samples (at diagnosis, post-neoadjuvant, and at 6- and 12-months of adjuvant treatment) in 41 stage IIIA NSCLC patients treated with perioperative nivolumab plus chemotherapy, included in the NADIM clinical trial (NCT03081689). Results were correlated with 5-year survival outcomes and validated through unsupervised clustering. An increase in the percentage of total B-cells (CD19+CD20+) and naïve B-cells (CD19+CD20+CD24+CD38+CD27−CD10−), along with a reduction in CD20 expression on total B-cells, a decrease in the proportion of memory B-cells (CD19+CD20+CD24+CD38−/lowCD27+) and transitional B-cells (CD19+CD20+CD24++CD38++CD10+), was observed during the time encompassed between the end of neoadjuvant treatment and the posterior 6 months of adjuvant treatment. Higher levels of CD20 expression on total B-cells, along with an increased percentage of memory B-cells, or activated B-cells (CD19+CD20+CD25+), at 6- and 12-months of adjuvant treatment, were associated with increased survival. Conversely, higher levels of a newly described circulating population of CD19+CD20lowCD25lowCD27low B-cells during adjuvant treatment were linked to disease progression. Perioperative nivolumab plus chemotherapy in resectable NSCLC patients induces significant changes in peripheral B-cells. The persistence of circulating memory B-cells during adjuvant treatment might play a crucial role in survival.https://www.tandfonline.com/doi/10.1080/2162402X.2025.2513109B lymphocyteschemoimmunotherapyflow cytometryNSCLCperioperative |
| spellingShingle | Belén Sierra Rodero Cristina Martínez-Toledo Ernest Nadal Marta Molina-Alejandre Rosario García Campelo Ángeles Gil-González Bartomeu Massuti Aránzazu García-Grande Manuel Dómine Amelia Insa Javier de Castro Carpeño Gerardo Huidobro Vence Margarita Majem Alex Martinez-Marti Diego Megias Daniel Lobato Ana Collazo-Lorduy Virginia Calvo Mariano Provencio Alberto Cruz-Bermúdez Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) OncoImmunology B lymphocytes chemoimmunotherapy flow cytometry NSCLC perioperative |
| title | Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) |
| title_full | Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) |
| title_fullStr | Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) |
| title_full_unstemmed | Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) |
| title_short | Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) |
| title_sort | peripheral memory b cell population maintenance and long term survival after perioperative chemoimmunotherapy in nsclc nadim trial |
| topic | B lymphocytes chemoimmunotherapy flow cytometry NSCLC perioperative |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2513109 |
| work_keys_str_mv | AT belensierrarodero peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT cristinamartineztoledo peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT ernestnadal peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT martamolinaalejandre peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT rosariogarciacampelo peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT angelesgilgonzalez peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT bartomeumassuti peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT aranzazugarciagrande peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT manueldomine peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT ameliainsa peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT javierdecastrocarpeno peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT gerardohuidobrovence peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT margaritamajem peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT alexmartinezmarti peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT diegomegias peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT daniellobato peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT anacollazolorduy peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT virginiacalvo peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT marianoprovencio peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial AT albertocruzbermudez peripheralmemorybcellpopulationmaintenanceandlongtermsurvivalafterperioperativechemoimmunotherapyinnsclcnadimtrial |